Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Ibuprofen Modified-Release vs Regular-Release in Healthy Volunteers
NCT05329454Phase 1Completed
- Sponsor
- Overseas Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibuprofen in chronic pain (6 arms), sponsored by Overseas Pharmaceuticals. Primary endpoints: Single-dose and multiple-dose bioavailability comparison between IBUMR and IBURed up to 30 days and Food effect of IBUMR on PK parameters up to 30 days. Started Dec 2020; status: completed.
02
Drugs
ibuprofen
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT05329454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329454.